• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

First-line bladder cancer therapy receives fast track designation

Article

The FDA has indicated that a new therapy for first-line nonmuscle-invasive bladder cancer meets the criteria for fast track designation.

The FDA has indicated that a new therapy for first-line nonmuscle-invasive bladder cancer meets the criteria for fast track designation.

A phase III clinical trial comparing the mycobacterial cell wall-DNA complex (MCC [Urocidin]) to the current standard therapy in patients with nonmuscle-invasive bladder cancer at high risk of recurrence or progression is scheduled to begin later this year. The study aims to demonstrate non-inferior efficacy with respect to disease-free survival and fewer toxicities than the current therapy, according to the drug’s manufacturer, Bioniche Life Sciences Inc.

“This is an important milestone for our phase III clinical development program with Urocidin,” said Graeme McRae, of Bioniche. “It highlights the need for a safer and more effective therapy for first-line bladder cancer patients. The FDA clearly recognizes that the current approved therapy is less than satisfactory and wishes to expedite the introduction of new therapies.”

The phase III study currently plans to enroll approximately 800 patients in North America, Australia, and Europe, and is a double-blind, randomized study. It will compare MCC to bacillus Calmette-Guerin (BCG [TheraCys, TICE BCG]), the standard treatment for patients with nonmuscle-invasive bladder cancer at high risk of recurrence or progression.

Related Videos
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
A panel of 4 experts on prostate cancer
A panel of experts on prostate cancer
A panel of 4 experts on prostate cancer
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
A panel of 4 experts on prostate cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.